Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced ...

Nck modulator reduced evidence of inflammation in an animal model of dermal irritation Compelling preclinical data support continued development of Nck modulators in atopic dermatitis CAMBRIDGE, Mass.

CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces the ...

AX-158, our lead Nck modulator, has shown strong, broad cytokine modulation as well as modulation of mixed lymphocyte reactions. Good data on therapeutic efficacy with AX-158 were observed in murine ...

CAMBRIDGE, Mass., Jan. 22, 2025 /PRNewswire/ -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement ...

Compelling preclinical data support continued development of Nck modulators in atopic dermatitis CAMBRIDGE, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Artax Biopharma, Inc., a clinical-stage ...